Background: Trachoma is the leading infectious cause of blindness. Patients with trachomatous corneal opacity (TCO) are traditionally considered high-risk cases for graft failure. However, anecdotal evidence suggests that corneal transplantation may restore vision in such individuals. We wanted to review the available evidence for keratoplasty outcomes in TCO.
Methods: A literature search of PubMed, MEDLINE, and Web of Science was performed using the search terms "trachoma* AND (keratoplasty OR cornea* transplant*)". The search was restricted to studies published between 1 January 1992 and 12 October 2022. All types of prospective and retrospective study designs reporting outcomes of keratoplasty in trachoma were included. The primary outcome assessed was rate of graft survival in patients with TCO who received keratoplasty. Secondary outcomes were postoperative best corrected visual acuity (BCVA) and graft rejection rates.
Results: Seven studies met our inclusion criteria. None were prospective trials; 215/302 grafts (71%) were clear at final follow-up. There was significant variability between studies in the reporting of patient characteristics, follow-up, complications, and outcomes. In data on penetrating keratoplasty (PKP), graft survival at final follow-up was observed in 161/195 eyes (83%). Studies assessing lamellar keratoplasty (LKP) reported graft survival in 18/20 eyes (90%). Rejection episodes were reported in 31/167 (19%) eyes managed with PKP and 0 of 20 eyes managed with LKP. Of 163 eyes, preoperative BCVA was ≤counting fingers in 76% and ≤6/60 in 91%. A postoperative BCVA of >6/60 was achieved in 63% of eyes.
Conclusions: There is a paucity of evidence supporting keratoplasty in TCO. However, it may hold visual rehabilitation promise for people whose needs have to date been largely ignored. More structured reporting of outcomes from centres which perform keratoplasty in TCO and a well-designed prospective study would be valuable additions to the literature.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573149 | PMC |
http://dx.doi.org/10.1371/journal.pntd.0012535 | DOI Listing |
Transfus Apher Sci
December 2024
University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Turkey; Ankara Yildirim Beyazit University, School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey.
Objective: Acute graft versus host disease (GVHD) occurs in 20-80 % of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Of these patients, 40 % will be resistant to steroids, which is the standard first-line approach. There is no standard second line treatment approach for patients with steroid refractory acute GVHD (SR-aGVHD).
View Article and Find Full Text PDFTransfus Apher Sci
December 2024
University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Turkey; Ankara Yildirim Beyazit University, School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey.
Objective: Vitamin D deficiency is common in adult patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT). Since vitamin D is an important regulatory factor for the immune system, vitamin D deficiency may have effects on antitumor activity, relapse rates, graft versus host disease (GVHD) occurrence and infection rates in allo-HSCT. We aimed to investigate the effects of vitamin D levels on the outcome of allo-HSCT.
View Article and Find Full Text PDFStem Cell Res Ther
December 2024
Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107, West Yan Jiang Road, Guangzhou, 510120, Guangdong, China.
Background: Allo-HSCT is a curative therapy for patients with transfusion-dependent thalassemia (TDT). The high incidence of transplant-related complications is becoming an obstacle to safe and effective unrelated donor (URD) transplantation.
Methods: In this retrospective study, we reported the survival outcomes and complications of transplantation in thalassemia patients using a novel regimen consisting of pre-transplantation immunosuppression (PTIS) and modified myeloablative conditioning based on intravenous busulfan, cyclophosphamide, fludarabine, and rabbit anti-human thymocyte immunoglobulin.
Best Pract Res Clin Gastroenterol
December 2024
Liver Intensive Care Unit, Centre Hépato-Biliaire, AP-HP, Hôpital Paul-Brousse, Université Paris-Saclay, Inserm research unit 1193, Villejuif, F-94800, France. Electronic address:
ABO-compatible Orthotopic Liver Transplantation (OLT) is the standard treatment for patients with acute liver failure (ALF) who meet the criteria for poor prognosis. Contraindications to liver transplantation may be related to the presence of severe medical or psychiatric comorbidities, or to an unstable clinical state incompatible with transplantation. Early mortality predictive scores and factors have been developed to identify futile transplantations that exacerbate organ shortage.
View Article and Find Full Text PDFOcul Surf
December 2024
Department of Prof. Cochereau, A. De Rothschild Foundation Hospital, Paris, France. Electronic address:
Purpose: Graft-versus-host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). GVHD may affect several organs, including ocular manifestations, ranging from dry eye syndrome to sight-threatening corneal ulceration or perforation. Limited information is available about characteristics and treatments of ocular GVHD and its relation to general prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!